Table 3.
Clinical trials with other statins
| Study | Population | Baseline mean LDL-C, mg/dL | N | Age range (mean ), y | No. in elderly subgroup (%); Age cutoff, y | Intervention | Mean follow-up, y | Endpoint | RRR, %; (p) | ARR, % | NNT, % |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Older patients | Younger patients | ||||||||||||
| Prosper | Vascular disease or smoking, HTN or DM | 147 | 5804 | 70–82 (75) | 5804 (100); ≥70 | Pravastatin 40 mg vs placebo | 3.2 | Coronary death, nonfatal MI and stroke | 15 (0.014) | 2.1 | 48 | – | |
| CHD death or nonfatal MI | 19 (0.006) | 2.1 | 48 | – | |||||||||
| 4S, Elderly | CHD | 188 | 4444a | 65–70 (67) | 1021 (23);a ≥65 | Simvastatin 20 mg vs placebo | 5.4 | All-cause mortality | 34 (0.009) | 6.2 | 16 | 40 | |
| CHD death | 43 (0.003) | 6 | 17 | 36 | |||||||||
| Major Coronary events | 34 (<0.001) | 9.8 | 10 | 12 | |||||||||
| Nonfatal MI | 33 (0.004) | 7.1 | 14 | 15 | |||||||||
| CARE, Elderly | CHD | 138 | 4259a | 65–75 (69) | 1283 (31);a ≥65 | Pravastatin 40 mg vs placebo | 5b | CHD death | 45 (0.004) | 4.6 | 22 | −250 | |
| Major coronary events | 32 (<0.001) | 9 | 11 | 20 | |||||||||
| Stroke | 40 (0.03) | 2.9 | 34 | 250 | |||||||||
| LIPID, Elderly | CHD | 148 | 9014a | 65–75 (NR) | 3514 (39);a ≥65 | Pravastatin 40 mg vs placebo | 6 | All-cause mortality | 21 (0.003) | 4.5 | 22 | 46 | |
| CHD death | 24 (0.009) | 2.9 | 35 | 71 | |||||||||
| MI | 26 (0.005) | 3.3 | 30 | 36 | |||||||||
| Stroke | 12 (>0.2) | 1.3 | 79 | 170 | |||||||||
| HPS | CHD, other occlusive arterial disease or DM | 131a | 20,536a | 40–80 (64)a | 10,697 (52);a ≥65 | Simvastatin 40 mg vs placebo | 5 | First major vascular event | 20c | 5.6c | 18c | 19 | |
| All-cause mortality | 13a (0.0003) | 1.8a | 56a | – | |||||||||
| CHD death or nonfatal MI | 27a (<0.0001) | 3.1a | 32a | – | |||||||||
| Stroke | 25a (<0.0001) | 1.4 | 72a | 19 | |||||||||
Note: PROSPER specifically and exclusively enrolled elderly participants.
a
Data from parent study, includes subjects < and ≥65 years.
b
Median.
c
Calculated from data for elderly subgroup.
Abbreviations: LDL-C, low-density lipoprotein cholesterol; RRR, relative risk reduction; ARR, absolute risk reduction; NNT, number needed to treat; CHD, Coronary heart disease; MI, Myocardial infarction; DM, diabetes mellitus; HTN, hypertension; NR, not reported; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; 4S, Scandinavian Simvastatin Survival Study; CARE, Cholesterol and Recurrent Events; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease; HPS, Heart Protection Study.